← Leaderboards
John D Crispino
University Of Chicago
$25,040,274
Attributed
$27,623,183
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,623,183 · 14
By mechanism
R01$16,734,555 · 7
R35$5,032,279 · 1
P50$2,552,240 · 1
P01$1,407,146 · 1
RC1$999,344 · 1
P30$753,569 · 1
Top collaborators
- Luis A. Nunes Amaral5 shared
- Richard W. Carthew5 shared
- Richard I. Morimoto5 shared
- Vasil V Galat2 shared
- Marcelo Bento Soares2 shared
- Michelle Alice Kelliher1 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Kunle O Odunsi$16,178,755
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesCellsLeukemiaHematopoieticIn VivoMutationMegakaryocytesHematopoiesisGata1 GeneInsightGene ExpressionPathway InteractionsMyeloproliferative DiseaseMegakaryocytopoiesesAffectLeadProgenitorAcute Megakaryocytic LeukemiasMalignant NeoplasmsCollaborationsBaseTranscription FactorDefectAnimal Model
Grant awards (75)
Identifying the mechanisms of leukemia progression$1,077,000
R35 · FY2025 · CA · contact PI
The role of the N-terminus of GATA1 in erythropoiesis$475,020
R01 · FY2025 · DK · contact PI
Project 2: Defining the Role of Megakaryocyte Abnormalities in the Progression of Primary Myelofibrosis$468,639
P01 · FY2025 · CA · contact PI
Identifying the mechanisms of leukemia progression$767,359
R35 · FY2024 · CA · contact PI
The role of the N-terminus of GATA1 in erythropoiesis$475,020
R01 · FY2024 · DK · contact PI
Project 2: Defining the Role of Megakaryocyte Abnormalities in the Progression of Primary Myelofibrosis$442,007
P01 · FY2024 · CA · contact PI
Identifying the mechanisms of leukemia progression$1,055,460
R35 · FY2023 · CA · contact PI
Project 2: Defining the Role of Megakaryocyte Abnormalities in the Progression of Primary Myelofibrosis$496,500
P01 · FY2023 · CA · contact PI
Identifying the mechanisms of leukemia progression$1,055,460
R35 · FY2022 · CA · contact PI
Identifying the mechanisms of leukemia progression$1,077,000
R35 · FY2021 · CA · contact PI
Identifying the pathways that drive progression of the MPNs to AML$415,273
R01 · FY2021 · CA · contact PI
Mechanisms of leukemogenesis in Down syndrome$383,681
R01 · FY2021 · CA · contact PI
Aberrant megakaryopoiesis in the myeloproliferative neoplasms.$418,851
R01 · FY2020 · HL · contact PI
Identifying the pathways that drive progression of the MPNs to AML$363,268
R01 · FY2020 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$241,587
P30 · FY2020 · CA · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$228,258
R01 · FY2020 · CA · contact PI
Aberrant megakaryopoiesis in the myleoproliferative neoplasms$131,494
R01 · FY2020 · HL · contact PI
Mechanisms of leukemogenesis in Down syndrome$125,555
R01 · FY2020 · CA · contact PI
Aberrant megakaryopoiesis in the myeloproliferative neoplasms.$450,538
R01 · FY2019 · HL · contact PI
Identifying the pathways that drive progression of the MPNs to AML$366,706
R01 · FY2019 · CA · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$327,592
R01 · FY2019 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$241,587
P30 · FY2019 · CA · contact PI
Aberrant megakaryopoiesis in the myeloproliferative neoplasms.$72,791
R01 · FY2019 · HL · contact PI
Aberrant megakaryopoiesis in the myeloproliferative neoplasms.$461,569
R01 · FY2018 · HL · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$337,725
R01 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$246,385
P30 · FY2018 · CA · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$167,480
R01 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$8,622
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$8,490
P30 · FY2018 · CA · contact PI
Cancer Research Career Enhancement and Related Activities$6,898
P30 · FY2018 · CA · contact PI
Aberrant megakaryopoiesis in the myeloproliferative neoplasms.$483,125
R01 · FY2017 · HL · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$336,656
R01 · FY2017 · CA · contact PI
GATA1 Mutation in Defective Erythropoiesis$330,363
R01 · FY2017 · DK · contact PI
Aberrant Megakaryopoiesis in the Myeloproliferative Neoplasms$422,223
R01 · FY2016 · HL · contact PI
GATA1 Mutation in Defective Erythropoiesis$330,363
R01 · FY2016 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$303,965
R01 · FY2016 · CA · contact PI
Aberrant Megakaryopoiesis in the Myeloproliferative Neoplasms$417,960
R01 · FY2015 · HL · contact PI
GATA1 Mutation in Defective Erythropoiesis$330,363
R01 · FY2015 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$303,965
R01 · FY2015 · CA · contact PI
Aberrant Megakaryopoiesis in the Myeloproliferative Neoplasms$417,308
R01 · FY2014 · HL · contact PI
GATA1 Mutation in Defective Erythropoiesis$330,363
R01 · FY2014 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$294,846
R01 · FY2014 · CA · contact PI
Aberrant Megakaryopoiesis in the Myeloproliferative Neoplasms$420,250
R01 · FY2013 · HL · contact PI
GATA1 Mutation in Defective Erythropoiesis$330,363
R01 · FY2013 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$285,728
R01 · FY2013 · CA · contact PI
CONSORTIUM: NORTHWESTERN UNIVERSITY$515,213
P50 · FY2012 · GM
Mechanisms of Leukemogenesis in Down Syndrome$303,965
R01 · FY2012 · CA · contact PI
Mechanisms of erythroblast enucleation$139,050
R56 · FY2012 · DK · contact PI
CONSORTIUM: NORTHWESTERN UNIVERSITY$486,180
P50 · FY2011 · GM
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$294,902
R01 · FY2011 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$292,358
R01 · FY2011 · CA · contact PI
FASEB SRC on Hematopoietic Malignancies$5,000
R13 · FY2011 · CA · contact PI
CONSORTIUM: NORTHWESTERN UNIVERSITY$507,273
P50 · FY2010 · GM
Identification of Altered Molecular Signature of Down Syndrome iPS Cells$499,344
RC1 · FY2010 · HL · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$301,396
R01 · FY2010 · CA · contact PI
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$299,472
R01 · FY2010 · DK · contact PI
CONSORTIUM: NORTHWESTERN UNIVERSITY$515,540
P50 · FY2009 · GM
Identification of Altered Molecular Signature of Down Syndrome iPS Cells$500,000
RC1 · FY2009 · HL · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$305,363
R01 · FY2009 · CA · contact PI
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$300,924
R01 · FY2009 · DK · contact PI
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$99,524
R01 · FY2009 · DK · contact PI
CONSORTIUM: NORTHWESTERN UNIVERSITY$528,034
P50 · FY2008 · GM
Mechanisms of Leukemogenesis in Down Syndrome$305,841
R01 · FY2008 · CA · contact PI
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$300,890
R01 · FY2008 · DK · contact PI
Role of Survivin in Development of Megakaryocytes and Erythroid Cells$308,212
R01 · FY2007 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$305,707
R01 · FY2007 · CA · contact PI
EPS: A Novel Hematopoietic Transcription Factor$306,562
R01 · FY2006 · DK · contact PI
Mechanisms of Leukemogenesis in Down Syndrome$293,825
R01 · FY2006 · CA · contact PI
EPS: A Novel Hematopoietic Transcription Factor$313,940
R01 · FY2005 · DK
Mechanisms of Leukemogenesis in Down Syndrome$300,896
R01 · FY2005 · CA
EPS: A Novel Hematopoietic Transcription Factor$313,940
R01 · FY2004 · DK
Mechanisms of Leukemogenesis in Down Syndrome$300,896
R01 · FY2004 · CA
EPS: A Novel Hematopoietic Transcription Factor$313,940
R01 · FY2003 · DK
Mechanisms of Leukemogenesis in Down Syndrome$300,896
R01 · FY2003 · CA
EPS: A Novel Hematopoietic Transcription Factor$332,444
R01 · FY2002 · DK